134 related articles for article (PubMed ID: 291436)
1. Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.
Harris AL; Potter C; Bunch C; Boutagy J; Harvey DJ; Grahame-Smith DG
Br J Clin Pharmacol; 1979 Sep; 8(3):219-27. PubMed ID: 291436
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia.
van Prooijen R; van der Kleijn E; Haanen C
Clin Pharmacol Ther; 1977 Jun; 21(6):744-50. PubMed ID: 266428
[TBL] [Abstract][Full Text] [Related]
3. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid.
Slevin ML; Piall EM; Aherne GW; Harvey VJ; Johnston A; Lister TA
J Clin Oncol; 1983 Sep; 1(9):546-51. PubMed ID: 6583325
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.
Donnette M; Solas C; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Hau LTT; Costello R; Ouafik L; Lacarelle B; Ciccolini J; Fanciullino R
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121770. PubMed ID: 31454720
[TBL] [Abstract][Full Text] [Related]
5. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.
Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC
Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.
Slevin ML; Piall EM; Aherne GW; Johnston A; Sweatman MC; Lister TA
Br J Clin Pharmacol; 1981 Oct; 12(4):507-10. PubMed ID: 6945865
[TBL] [Abstract][Full Text] [Related]
7. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
Breithaupt H; Pralle H; Eckhardt T; von Hattingberg M; Schick J; Löffler H
Cancer; 1982 Oct; 50(7):1248-57. PubMed ID: 7104969
[TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
Sinkule JA; Evans WE
J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
[TBL] [Abstract][Full Text] [Related]
9. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
[TBL] [Abstract][Full Text] [Related]
10. Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.
Yang GS; Wang C; Minkin S; Minden MD; McCulloch EA
J Cell Physiol; 1991 Jul; 148(1):60-7. PubMed ID: 1860896
[TBL] [Abstract][Full Text] [Related]
11. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
12. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy?
van Prooijen HC; Muus P; Roelofs JM; Punt K
Scand J Haematol; 1986 Jan; 36(1):123-6. PubMed ID: 3456631
[TBL] [Abstract][Full Text] [Related]
13. High doses of cytosine arabinoside (HD-Ara-C) as reinforcement during remission of acute myeloid leukemia.
Zittoun R; Marie JP; Pommier Y; Pochat L
Med Pediatr Oncol; 1982; 10 Suppl 1():259-61. PubMed ID: 6962322
[TBL] [Abstract][Full Text] [Related]
14. [Relation between plasma Ara-C and intracellular Ara-CTP levels by intermediate dose and high dose Ara-C administration in the treatment of AML].
Yoshida T; Kobayashi K; Nakamura S; Ohtake S; Itoh K; Kanno M; Hirai J; Yasushi ; Matsuda TT
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):625-30. PubMed ID: 3162669
[TBL] [Abstract][Full Text] [Related]
15. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Ghaddar HM; Plunkett W; Kantarjian HM; Pierce S; Freireich EJ; Keating MJ; Estey EH
Leukemia; 1994 Aug; 8(8):1269-74. PubMed ID: 8057660
[TBL] [Abstract][Full Text] [Related]
16. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
te Boekhorst PA; Löwenberg B; Sonneveld P
Leukemia; 1994 Sep; 8(9):1480-6. PubMed ID: 7522289
[TBL] [Abstract][Full Text] [Related]
18. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Gandhi V; Estey E; Keating MJ; Plunkett W
J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia.
Zittoun R; Marie JP; Delanian S; Suberville AM; Thevenin D
Semin Oncol; 1987 Jun; 14(2 Suppl 1):269-75. PubMed ID: 3473680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
